Investing in a healthy future.

We are facing an escalating mental health crisis, yet available treatments remain limited and insufficiently effective. In the U.S. alone, over 12 million people suffer from PTSD, 20 million struggle with depression, and nearly 20 million battle substance use disorders.

Psychedelic-assisted therapy represents one of the most effective mental health treatments ever studied. In MAPS' Phase III clinical trials, 67% of participants treated with MDMA no longer met the diagnostic criteria for PTSD after suffering for an average of 14 years, and 88% experienced significant symptom improvement after only three sessions. Promising outcomes have also been observed with psilocybin-assisted therapy for depression, LSD for generalized anxiety, and 5-MeO-DMT for depression.

We actively invest in pioneering research into these transformative compounds, as well as critical policy and advocacy efforts, initiatives to ensure equitable access, and education and safety programs.

Please explore the work of these incredible organizations: PSFC, The Coalition for Psychedelic Safety and Education, The Psychedelic Mental Health Access Alliance, The University Psychedelic Education Program (U-PEP), SHINE Collective, End Chronic Disease, Ripples, MAPS, Sunstone Therapies, Fireside Project, and the Healing Advocacy Fund, as well as these brilliant scientists: Dr. Nolan Williams at Stanford University, Dr. David Yaden at John Hopkins University, Dr. Alex Lehmann at McGill University, Dr. Gul Dolen at Berkeley, and Dr. Robin Carhart-Harris at UCSF.